3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS

Muscle and Nerve

Volumn 40, Issue 5, 2009, Pages 795-800

  Oh, Shin J ^a   Claussen, Gwendolyn G ^a   Hatanaka, Yuki ^a   Morgan, Marla B ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

3,4 DAP; Clinical trial; Diaminopyridine; Drug study; Lambert Eaton myasthenic syndrome; LEMS; Myasthenic syndrome; Treatment of LEMS

Indexed keywords

3,4 DIAMINOPYRIDINE; GUANIDINE; PLACEBO; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; EATON LAMBERT SYNDROME; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MUSCLE WEAKNESS; NERVE STIMULATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLEX; SLEEP DISORDER;

4-AMINOPYRIDINE; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES;

EID: 71549131003     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21422     Document Type: Article

References (16)

1. Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 1983;22:260-265.
2. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms LD, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders (EFNS Task Force Article). Eur J Neurol 2006;13:691-699.
3. Oh SJ, Kurokawa K, Claussen GC, Ryan HF. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515-520. (Pubitemid 41395985)
4. Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34:1324-1330.
5. Oh SJ, Kim D, Kuruoglu R, Brooks J, Claussen GC. Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1996;19:903-906. (Pubitemid 26190653)
6. Jaretzki A III, Barohn RN, Ernsthoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000;55:16-23.
7. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772. (Pubitemid 28362935)
8. Lambert EH, Rooke ED, Eaton LM, Hodgson CH, et al. Myasthenic syndrome occasionally associated with brachial neoplasm: neurophysiological studies. In Viets HR, editor. Myasthenia gravis: the second international symposium proceedings 1959.Springfield, IL: Charles C. Thomas;1961. p. 362-410.
9. Oh SJ. Electromyography. Neuromuscular transmission studies. Baltimore: Williams & Wilkins; 1988.
10. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1982;321:1567-1571.
11. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diamnopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-607. (Pubitemid 30082925)
12. Wirtz PW, van Gerven JMA, van Dijk JG, Schoemaker HC, den Hartigh AR, Verschuuren JJ. The effect of 3,4-diaminopyridine (DAP) and pyridostigmine (PS) on muscle function in the Lambert-Eaton myasthenic syndrome (LEMS): a double-blind placebo-controlled study [abstract]. Neuromuscul Dis 2002;7:760.
13. Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 1993;88:136-140. (Pubitemid 23247977)
14. Oh SJ. The Eaton-Lambert syndrome in ocular myasthenia gravis. Arch Neurol 1974;31:183-186.
15. Oh SJ, Kim DS, Head TC, Claussen GC. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997;20:1146-1152.
16. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005;2: CD003279.